Abstract
T-cell development is a major physiological process occurring in complex organisms, that ensures the formation of T-cell receptors diverse repertoire, to recognize antigens throughout the life of the organism. The thymus offers a microenvironment for efficient development, where progenitor populations go through maturation steps, which, when not regulated, are associated with disease onset, including autoimmune disorders and cancer. Glycosylation is a major post-translational modification that occurs in virtually all cells, including T lymphocytes, regulating receptor- turnover, affinity and signaling. However, there is a missing knowledge on how glycans regulate lymphocyte development and their impact in T-cell functions. We discovered stage-specific glycosylation profiles in human and murine thymocyte populations. Thereafter, we generated two glycoengineered mouse models displaying N-glycosylation pathway deficiencies, at early DN stages, lacking the Mgat1 or Mgat2 genes. We demonstrated remarkable defects in key T-cell developmental stages, such as ß- and DP-selection, natural regulatory T-cell generation, γδ T development/differentiation and thymic egression, in Mgat1-deficient thymocytes, indicating a pathogenic role of mannose N-glycans in development. We also demonstrated that a single N- glycan antenna (modelled in Mgat2-deficient thymocytes) is sufficient to rescue key developmental processes. In conclusion, we demonstrated that mannosylated thymocytes render a dysregulation in T-cell development, associated with disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Portuguese Foundation for Science and Technology (FCT), projects NORTE-01-0145-FEDER-000029, POCI-01/ 0145-FEDER-016601, POCI-01-0145-FEDER-028772, PTDC/MEC17 REU/28772/2017 (SSP); Grant from Portuguese group of study in autoimmune diseases (NEDAI) to SSP. MMV [PD/BD/135452/2017] and IA [SFRH/BD/128874/2017] received funding from the FCT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethical Boards of Faculty of Medicine of the University of Lisbon and of Hospital de Santa Cruz, Carnaxide, Portugal.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data analysed during this study are included in the manuscript, in the source data files. Further information and requests for resources and reagents should be directed and will be fulfilled to the Lead Contact Salome S Pinho.
